Mr. Soika transitions into the COO position from his post on the advisory board of Heart Test Laboratories, Inc., where he has served since the company’s incorporation. His appointment as COO comes in anticipation of the company’s move from initial development stage into marketing, sales and manufacturing of their flagship device, the MyoVista Cardiac Diagnostic System.
With more than four decades of medical device experience, Mr. Soika brings an array of knowledge and talents to the HTL team. During the course of his career, he has held President/CEO positions for several medical device companies, including Criticare Systems and a division of Baxter Healthcare. Additionally, he has been issued multiple medical device patents.
“Engaging Emil Soika as COO is an integral step in our continued growth at Heart Test Labs,” said Drew Diaz, CEO of Heart Test Laboratories, Inc. “As we move into the launch phase of the MyoVista, his expertise in business management and development will be invaluable.”
The MyoVista, the flagship product of Heart Test Laboratories, Inc, is a portable, affordable, diagnostic device used to determine the presence and level of life-threatening myocardial abnormalities and the obstruction of coronary arteries.